Eosinophilic inflammation can drive recurrent nasal polyps1,2

Recurrent nasal polyps and eosinophilic inflammation

Up to 90% of nasal polyps have predominantly eosinophilic inflammation

*Based on studies that examined the presence of eosinophil leukocyte infiltration in nasal polyp biopsy tissue of patients in the US and Europe.1-4

After surgery, nasal polyp recurrence was three times greater in patients with elevated eosinophils

†Based on a retrospective, single-center study to investigate the relationship between eosinophil density in nasal polyp tissue and recurrence in adults who underwent endoscopic sinus surgery for massive nasal polyposis (filled at least half of each nostril). Patients were categorized as higher density (>4 eosinophils/1000 μm2) or lower density (≤3 eosinophils/1000 μm2) by examining digital images taken at x400 magnification.2

NP=nasal polyp.

Elevated eosinophils in nasal polyps are associated with1-4:

  • Presence of INFLAMMATION
  • Greater likelihood of NASAL POLYP RECURRENCE after surgical removal

How NUCALA targets eosinophils

Diagram showing how NUCALA (mepolizumab) targets eosinophils

The MOA of NUCALA in CRSwNP has not been definitively established.

  • IL-5 binds to complex on EOS

    Interleukin-5 (IL-5) is the major cytokine responsible for eosinophil growth and survival. IL-5 binds to the IL-5 receptor complex expressed on the eosinophil surface. 

  • How IL-5 impacts EOS

    Downstream signaling by IL-5 promotes the growth and differentiation, recruitment, activation, and survival of eosinophils. 

  • NUCALA targets IL-5

    NUCALA, a humanized monoclonal antibody, targets IL-5 and binds to it. NUCALA blocks IL-5 binding to the alpha chain of the IL-5 receptor complex. 

  • How NUCALA reduces EOS

    NUCALA inhibits IL-5 signaling, reducing the production and survival of eosinophils.

Reduced blood eosinophil levels and maintained within normal‡ levels5,6

 

NUCALA reduced blood eosinophil levels and maintained within normal levels NUCALA reduced blood eosinophil levels and maintained within normal levels
80% reduction in blood eosinophil levels with NUCALA at Week 4, maintained at 84% at Week 52 80% reduction in blood eosinophil levels with NUCALA at Week 4, maintained at 84% at Week 52

in blood eosinophil levels with NUCALA at Week 4, maintained at 84% at Week 525,6

NUCALA ratio to baseline: Week 4, 0.20; Week 52, 0.16.

All results are descriptive. The clinical significance of these pharmacodynamic data is unknown.

Mean blood eosinophil levels (NUCALA, placebo)
• Baseline: 390 cells/µL, 400 cells/µL
• At Week 52: 60 cells/µL, 360 cells/µL

All results are descriptive. The clinical significance of these pharmacodynamic data is unknown.

‡Mean normal blood eosinophil levels in a general population of subjects without confounding factors have been reported as 100 cells/µL (range: 34-257) and 107 cells/µL (5th, 95th percentile: 30, 395); levels vary based on age, sex, environmental exposures, and comorbid conditions.7,8

SYNAPSE study design

What role do blood eosinophils play?

Eosinophils play a role in maintaining health, including regulation of the immune system, regenerating and repairing tissue, and protecting the host (eg, defending the body against parasitic infection).9 In CRSwNP, however, elevated eosinophils are a key driver of CRSwNP pathophysiology, including inflammation.2,3

Nasal polyps patient Marco eating takeout food with three friends Nasal polyps patient Marco eating takeout food with three friends

WHICH OF YOUR CRSwNP PATIENTS COULD BENEFIT
FROM NUCALA?

WHICH OF YOUR CRSwNP PATIENTS COULD BENEFIT FROM NUCALA?

GO TO PATIENT PROFILES
Nasal polyps patient Janet drinking coffee while talking to man on couch Nasal polyps patient Janet drinking coffee while talking to man on couch

EXPLORE NUCALA DATA IN CRSwNP PATIENTS

 

VIEW NUCALA EFFICACY